Study Purpose:
Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibodyStudy Status:
Not yet recruiting
Disease:
Amyotrophic Lateral Sclerosis , Plasmapheresis
Study Type:
Interventional
Type of Intervention:
Procedure
Intervention Name:
Plasmapheresis
Placebo:
No
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
N/A
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Li-Kai Tsai, MD., Ph.D. / email hidden; JavaScript is required / 886-2-23123456
Study Sponsor:
National Taiwan University Hospital
Estimated Enrollment:
20
Estimated Study Start Date:
11 / 01 / 2022
Estimated Study Completion Date:
03 / 31 / 2025
Posting Last Modified Date:
10 / 05 / 2022
Date Study Added to neals.org:
10 / 03 / 2022
Minimum Age:
20 Years
Maximum Age:
N/A
Inclusion Criteria:1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.
2. Agree to receive plasmapheresis intervention.
3. Agree to participate in the trial and receive serial examinations and follow up.
Exclusion Criteria:
1. Patients without plasma anti-NRIP autoantibody.
2. Patients requiring permanent ventilator support for ALS progression.
3. Not able to receive plasmapheresis or trial-related examinations.
4. Under pregnancy.
5. Blood fibrinogen level less than 50 mg/dl.
6. Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.